temozolomide has been researched along with Colorectal Cancer in 37 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Non-randomized studies showed that temozolomide (TMZ) achieves an average 10% response rate in heavily pretreated metastatic colorectal cancer (mCRC) patients with promoter methylation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT)." | 9.27 | Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. ( Antista, M; Barault, L; Battaglia, L; Belfiore, A; Berenato, R; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Di Nicolantonio, F; Falcone, A; Martinetti, A; Milione, M; Morano, F; Moretto, R; Nichetti, F; Niger, M; Perrone, F; Pietrantonio, F; Pruneri, G; Raimondi, A; Randon, G, 2018) |
| "Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylation." | 9.22 | Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. ( Amatu, A; Barault, L; Bardelli, A; Bencardino, K; Bonazzina, E; Cassingena, A; Chirico, G; Cipani, T; Crivori, P; Di Nicolantonio, F; Esteller, M; Gatto, R; Ghezzi, S; Marrapese, G; Moutinho, C; Palmeri, L; Ricotta, R; Sartore-Bianchi, A; Siena, S; Tosi, F; Truini, M, 2016) |
| "In a phase II study, we showed that temozolomide (TMZ) was tolerable and active in heavily pre-treated patients with advanced colorectal cancer (CRC) and MGMT methylation." | 7.83 | Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. ( Berenato, R; Bossi, I; Caporale, M; de Braud, F; Di Bartolomeo, M; Dotti, KF; Federici, S; Festinese, F; Iacovelli, R; Leone, G; Maggi, C; Milione, M; Pellegrinelli, A; Perrone, F; Pietrantonio, F; Tamborini, E, 2016) |
| "The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade." | 7.11 | Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. ( Amatu, A; Barault, L; Bardelli, A; Bartolini, A; Battuello, P; Bonoldi, E; Cassingena, A; Crisafulli, G; Di Nicolantonio, F; Germano, G; Idotta, L; Lazzari, L; Luraghi, P; Macagno, M; Marsoni, S; Mauri, G; Morano, F; Personeni, N; Pessei, V; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F; Valtorta, E; Vitiello, PP; Zampino, MG, 2022) |
| " If further studies are to be performed, emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated." | 6.73 | A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. ( Khan, OA; Levitt, NC; Margison, GP; Michael, M; Middleton, MR; Midgley, R; Mortimer, P; Olver, I; Ranson, M; Watson, AJ, 2008) |
| "Temozolomide is an oral alkylating agent used for treating several cancers including glioblastoma and melanoma." | 6.66 | Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. ( Benelli, M; de Braud, F; Di Donato, S; Pietrantonio, F; Randon, G; Romagnoli, D, 2020) |
| "The overall lifetime risk of developing colorectal cancer is 1 in 22 in men and 1 in 24 in women." | 5.62 | Temozolomide modulates the expression of miRNAs in colorectal cancer. ( Abdel-Ghany, S; Alqosaibi, AI; Sabit, H, 2021) |
| "Incubation of HCT116 colorectal cancer cells with LA altered their glutathione pool and caused a decline in MGMT activity." | 5.42 | Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction. ( Dörsam, B; Fahrer, J; Göder, A; Kaina, B; Kraus, A; Nagel, G; Seiwert, N, 2015) |
| "Non-randomized studies showed that temozolomide (TMZ) achieves an average 10% response rate in heavily pretreated metastatic colorectal cancer (mCRC) patients with promoter methylation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT)." | 5.27 | Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. ( Antista, M; Barault, L; Battaglia, L; Belfiore, A; Berenato, R; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Di Nicolantonio, F; Falcone, A; Martinetti, A; Milione, M; Morano, F; Moretto, R; Nichetti, F; Niger, M; Perrone, F; Pietrantonio, F; Pruneri, G; Raimondi, A; Randon, G, 2018) |
| " Five clinical trials with temozolomide or dacarbazine have been performed in metastatic colorectal cancer (mCRC) with selection based on methyl-specific PCR (MSP) testing with modest results." | 5.24 | Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. ( Amatu, A; Barault, L; Bardelli, A; Berenato, R; Caporale, M; Cassingena, A; De Braud, F; Di Nicolantonio, F; Falcomatà, C; Ghezzi, S; Milione, M; Nichelatti, M; Pellegrinelli, A; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F, 2017) |
| "Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylation." | 5.22 | Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. ( Amatu, A; Barault, L; Bardelli, A; Bencardino, K; Bonazzina, E; Cassingena, A; Chirico, G; Cipani, T; Crivori, P; Di Nicolantonio, F; Esteller, M; Gatto, R; Ghezzi, S; Marrapese, G; Moutinho, C; Palmeri, L; Ricotta, R; Sartore-Bianchi, A; Siena, S; Tosi, F; Truini, M, 2016) |
| "In a phase II study, we showed that temozolomide (TMZ) was tolerable and active in heavily pre-treated patients with advanced colorectal cancer (CRC) and MGMT methylation." | 3.83 | Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. ( Berenato, R; Bossi, I; Caporale, M; de Braud, F; Di Bartolomeo, M; Dotti, KF; Federici, S; Festinese, F; Iacovelli, R; Leone, G; Maggi, C; Milione, M; Pellegrinelli, A; Perrone, F; Pietrantonio, F; Tamborini, E, 2016) |
| " Cutoff values of MGMT methylation specific for metastatic colorectal cancer (mCRC) tissue samples were established in a cohort of 60 patients treated with dacarbazine." | 3.81 | Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. ( Amatu, A; Barault, L; Bardelli, A; Bleeker, FE; Cassingena, A; Cassoni, P; De Braud, F; de Witt Hamer, P; Di Nicolantonio, F; Esteller, M; Falcomatà, C; Fiano, V; Milione, M; Moutinho, C; Pietrantonio, F; Rudà, R; Sartore-Bianchi, A; Siena, S; Siravegna, G; Soffietti, R; Venesio, T; Wesseling, P, 2015) |
| " Two compounds in this series were found to potentiate the cytotoxicity of the DNA-methylating agent temozolomide by 4-5-fold in a human colorectal cancer cell line." | 3.72 | Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. ( Curtin, NJ; Eastman, BW; Golding, BT; Griffin, RJ; Hostomsky, Z; Kyle, S; Li, J; Maegley, KA; Skalitzky, DJ; Webber, SE; White, AW; Yu, XH, 2004) |
| "Spectral analysis could distinguish tumour kinetics from normal tissue kinetics in an individual [11C]-temozolomide study and demonstrated a markedly greater volume of distribution (VD) in glioma than in normal brain, although there was no appreciable difference in mean residence time." | 3.70 | Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. ( Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P, 1998) |
| "The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade." | 3.11 | Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. ( Amatu, A; Barault, L; Bardelli, A; Bartolini, A; Battuello, P; Bonoldi, E; Cassingena, A; Crisafulli, G; Di Nicolantonio, F; Germano, G; Idotta, L; Lazzari, L; Luraghi, P; Macagno, M; Marsoni, S; Mauri, G; Morano, F; Personeni, N; Pessei, V; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F; Valtorta, E; Vitiello, PP; Zampino, MG, 2022) |
| " If further studies are to be performed, emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated." | 2.73 | A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. ( Khan, OA; Levitt, NC; Margison, GP; Michael, M; Middleton, MR; Midgley, R; Mortimer, P; Olver, I; Ranson, M; Watson, AJ, 2008) |
| "Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 and subsequently was given orally up to 1,200 mg m-2." | 2.67 | Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). ( Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS, 1992) |
| "Temozolomide is an oral alkylating agent used for treating several cancers including glioblastoma and melanoma." | 2.66 | Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. ( Benelli, M; de Braud, F; Di Donato, S; Pietrantonio, F; Randon, G; Romagnoli, D, 2020) |
| "The overall lifetime risk of developing colorectal cancer is 1 in 22 in men and 1 in 24 in women." | 1.62 | Temozolomide modulates the expression of miRNAs in colorectal cancer. ( Abdel-Ghany, S; Alqosaibi, AI; Sabit, H, 2021) |
| "Incubation of HCT116 colorectal cancer cells with LA altered their glutathione pool and caused a decline in MGMT activity." | 1.42 | Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction. ( Dörsam, B; Fahrer, J; Göder, A; Kaina, B; Kraus, A; Nagel, G; Seiwert, N, 2015) |
| "Most drugs used for colorectal cancer therapy induce DNA-alkylation damage, which is primarily repaired by the base excision repair (BER) pathway." | 1.37 | DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer. ( Aneja, R; Banerjee, S; Jaiswal, AS; Narayan, S; Ostrov, DA; Sarkar, FH, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 6 (16.22) | 29.6817 |
| 2010's | 18 (48.65) | 24.3611 |
| 2020's | 11 (29.73) | 2.80 |
| Authors | Studies |
|---|---|
| Qin, L | 1 |
| Huiwen, M | 1 |
| Wang, J | 1 |
| Wang, Y | 1 |
| Khan, SA | 1 |
| Zhang, Y | 2 |
| Qiu, H | 1 |
| Jiang, L | 1 |
| He, L | 1 |
| Jia, S | 1 |
| Morano, F | 5 |
| Raimondi, A | 4 |
| Pagani, F | 3 |
| Lonardi, S | 2 |
| Salvatore, L | 1 |
| Cremolini, C | 2 |
| Murgioni, S | 2 |
| Randon, G | 5 |
| Palermo, F | 2 |
| Antonuzzo, L | 1 |
| Pella, N | 1 |
| Racca, P | 1 |
| Prisciandaro, M | 1 |
| Niger, M | 2 |
| Corti, F | 1 |
| Bergamo, F | 1 |
| Zaniboni, A | 1 |
| Ratti, M | 1 |
| Palazzo, M | 1 |
| Cagnazzo, C | 1 |
| Calegari, MA | 3 |
| Marmorino, F | 1 |
| Capone, I | 1 |
| Conca, E | 1 |
| Busico, A | 2 |
| Brich, S | 1 |
| Tamborini, E | 4 |
| Perrone, F | 5 |
| Di Maio, M | 2 |
| Milione, M | 7 |
| Di Bartolomeo, M | 6 |
| de Braud, F | 9 |
| Pietrantonio, F | 11 |
| Crisafulli, G | 1 |
| Sartore-Bianchi, A | 6 |
| Lazzari, L | 1 |
| Amatu, A | 4 |
| Macagno, M | 2 |
| Barault, L | 7 |
| Cassingena, A | 4 |
| Bartolini, A | 1 |
| Luraghi, P | 1 |
| Mauri, G | 1 |
| Battuello, P | 1 |
| Personeni, N | 1 |
| Zampino, MG | 1 |
| Pessei, V | 1 |
| Vitiello, PP | 1 |
| Tosi, F | 3 |
| Idotta, L | 1 |
| Valtorta, E | 1 |
| Bonoldi, E | 1 |
| Germano, G | 1 |
| Di Nicolantonio, F | 7 |
| Marsoni, S | 1 |
| Siena, S | 5 |
| Bardelli, A | 4 |
| Willis, JA | 1 |
| Overman, MJ | 1 |
| Ko, HJ | 1 |
| Chiou, SJ | 1 |
| Tsai, CY | 1 |
| Loh, JK | 1 |
| Lin, XY | 1 |
| Tran, TH | 1 |
| Hou, CC | 1 |
| Cheng, TS | 1 |
| Lai, JM | 1 |
| Chang, PM | 1 |
| Wang, FS | 1 |
| Su, CL | 1 |
| Huang, CF | 1 |
| Hong, YR | 1 |
| Lobefaro, R | 1 |
| Antista, M | 2 |
| Mosconi, S | 1 |
| Rimassa, L | 1 |
| Tomasello, G | 1 |
| Longarini, R | 1 |
| Farina, G | 1 |
| Petrelli, F | 1 |
| Gori, S | 2 |
| Corallo, S | 3 |
| Guarini, V | 1 |
| Martinetti, A | 3 |
| Fucà, G | 2 |
| Romagnoli, D | 1 |
| Di Donato, S | 1 |
| Benelli, M | 1 |
| Ottaiano, A | 1 |
| Caraglia, M | 1 |
| DuRoss, AN | 1 |
| Landry, MR | 1 |
| Thomas, CR | 1 |
| Neufeld, MJ | 1 |
| Sun, C | 1 |
| Alqosaibi, AI | 1 |
| Abdel-Ghany, S | 1 |
| Sabit, H | 1 |
| Inno, A | 1 |
| Monterisi, S | 1 |
| Orlandi, A | 2 |
| Santini, D | 1 |
| Basso, M | 1 |
| Cassano, A | 1 |
| Martini, M | 2 |
| Cenci, T | 1 |
| de Pascalis, I | 2 |
| Camarda, F | 1 |
| Barbaro, B | 1 |
| Larocca, LM | 1 |
| Tonini, G | 1 |
| Barone, C | 2 |
| Yang, Z | 1 |
| Wei, D | 1 |
| Liu, F | 1 |
| Liu, J | 1 |
| Wu, X | 1 |
| Stevens, MFG | 1 |
| Bradshaw, TD | 2 |
| Luo, Y | 1 |
| Zhang, J | 2 |
| Berenato, R | 3 |
| Moretto, R | 1 |
| Belfiore, A | 2 |
| Nichetti, F | 1 |
| Battaglia, L | 1 |
| Pruneri, G | 1 |
| Falcone, A | 1 |
| Schwartz, S | 1 |
| Szeto, C | 1 |
| Tian, Y | 1 |
| Cecchi, F | 1 |
| Benz, S | 1 |
| Hembrough, T | 1 |
| Hochhauser, D | 1 |
| Glynne-Jones, R | 1 |
| Potter, V | 1 |
| Grávalos, C | 1 |
| Doyle, TJ | 1 |
| Pathiraja, K | 1 |
| Zhang, Q | 1 |
| Zhang, L | 2 |
| Sausville, EA | 1 |
| Castano, A | 1 |
| Maggi, C | 2 |
| Bossi, I | 2 |
| Gevorgyan, A | 1 |
| Biondani, P | 1 |
| Pacifici, M | 1 |
| Gariboldi, M | 1 |
| Festinese, F | 2 |
| Jaiswal, AS | 2 |
| Panda, H | 1 |
| Law, BK | 1 |
| Sharma, J | 1 |
| Jani, J | 1 |
| Hromas, R | 1 |
| Narayan, S | 2 |
| Göder, A | 1 |
| Nagel, G | 1 |
| Kraus, A | 1 |
| Dörsam, B | 1 |
| Seiwert, N | 1 |
| Kaina, B | 1 |
| Fahrer, J | 1 |
| Bleeker, FE | 1 |
| Moutinho, C | 2 |
| Falcomatà, C | 2 |
| Fiano, V | 1 |
| Siravegna, G | 1 |
| Cassoni, P | 1 |
| Rudà, R | 1 |
| Soffietti, R | 1 |
| Venesio, T | 1 |
| Wesseling, P | 1 |
| de Witt Hamer, P | 1 |
| Esteller, M | 2 |
| Iacovelli, R | 1 |
| Dotti, KF | 1 |
| Caporale, M | 2 |
| Leone, G | 1 |
| Pellegrinelli, A | 2 |
| Federici, S | 1 |
| Wickström, M | 1 |
| Dyberg, C | 1 |
| Milosevic, J | 1 |
| Einvik, C | 1 |
| Calero, R | 1 |
| Sveinbjörnsson, B | 1 |
| Sandén, E | 1 |
| Darabi, A | 1 |
| Siesjö, P | 1 |
| Kool, M | 1 |
| Kogner, P | 1 |
| Baryawno, N | 1 |
| Johnsen, JI | 1 |
| Bencardino, K | 1 |
| Ghezzi, S | 2 |
| Palmeri, L | 1 |
| Bonazzina, E | 1 |
| Ricotta, R | 1 |
| Cipani, T | 1 |
| Crivori, P | 1 |
| Gatto, R | 1 |
| Chirico, G | 1 |
| Marrapese, G | 1 |
| Truini, M | 1 |
| Zeng, J | 1 |
| Zeng, Z | 1 |
| Wang, F | 1 |
| Wang, D | 1 |
| Chen, C | 1 |
| Li, C | 1 |
| An, X | 1 |
| Xu, R | 1 |
| Huang, P | 1 |
| Ba, Y | 1 |
| Li, Y | 1 |
| Nichelatti, M | 1 |
| Shacham-Shmueli, E | 1 |
| Beny, A | 1 |
| Geva, R | 1 |
| Blachar, A | 1 |
| Figer, A | 1 |
| Aderka, D | 1 |
| Banerjee, S | 1 |
| Aneja, R | 1 |
| Sarkar, FH | 1 |
| Ostrov, DA | 1 |
| Stevens, MF | 2 |
| Hummersone, M | 1 |
| Madhusudan, S | 1 |
| Laughton, CA | 1 |
| Calabrese, CR | 2 |
| Almassy, R | 1 |
| Barton, S | 1 |
| Batey, MA | 2 |
| Calvert, AH | 1 |
| Canan-Koch, S | 1 |
| Durkacz, BW | 1 |
| Hostomsky, Z | 3 |
| Kumpf, RA | 1 |
| Kyle, S | 3 |
| Li, J | 2 |
| Maegley, K | 1 |
| Newell, DR | 2 |
| Notarianni, E | 1 |
| Stratford, IJ | 1 |
| Skalitzky, D | 2 |
| Thomas, HD | 2 |
| Wang, LZ | 2 |
| Webber, SE | 3 |
| Williams, KJ | 1 |
| Curtin, NJ | 3 |
| White, AW | 1 |
| Eastman, BW | 1 |
| Golding, BT | 1 |
| Maegley, KA | 2 |
| Skalitzky, DJ | 1 |
| Yu, XH | 1 |
| Griffin, RJ | 1 |
| Canan, S | 1 |
| Ku, GY | 1 |
| Krol, G | 1 |
| Ilson, DH | 1 |
| Steckley, JL | 1 |
| Watling, CJ | 1 |
| Ng, W | 1 |
| Khan, OA | 1 |
| Ranson, M | 1 |
| Michael, M | 1 |
| Olver, I | 1 |
| Levitt, NC | 1 |
| Mortimer, P | 1 |
| Watson, AJ | 1 |
| Margison, GP | 1 |
| Midgley, R | 1 |
| Middleton, MR | 1 |
| Meikle, SR | 1 |
| Matthews, JC | 1 |
| Brock, CS | 1 |
| Wells, P | 1 |
| Harte, RJ | 1 |
| Cunningham, VJ | 1 |
| Jones, T | 1 |
| Price, P | 1 |
| Newlands, ES | 1 |
| Blackledge, GR | 1 |
| Slack, JA | 1 |
| Rustin, GJ | 1 |
| Smith, DB | 1 |
| Stuart, NS | 1 |
| Quarterman, CP | 1 |
| Hoffman, R | 1 |
| Brampton, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Dynamic Hypermutation Status[NCT03519412] | Phase 2 | 102 participants (Anticipated) | Interventional | 2019-01-23 | Active, not recruiting | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter[NCT00423150] | Phase 2 | 86 participants (Actual) | Interventional | 2007-01-26 | Terminated | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Tumor response rate was based on Response Evaluation Criteria in Solid Tumors (RECIST).~Complete Response (CR): Disappearance of all target lesions.~Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD." (NCT00423150)
Timeframe: From start of treatment until participant's disease progression, intolerable toxicity or death, which ever comes first
| Intervention | Participants (Number) | |
|---|---|---|
| Number of participants with Complete Response | Number of participants with Partial Response | |
| Temozolomide | 0 | 5 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
1 review available for temozolomide and Colorectal Cancer
| Article | Year |
|---|---|
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
12 trials available for temozolomide and Colorectal Cancer
| Article | Year |
|---|---|
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Humans; Ipi | 2022 |
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Dacarbaz | 2022 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Methylation; DNA Mod | 2018 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms; | 2019 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2013 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Surv | 2014 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DN | 2016 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2017 |
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
24 other studies available for temozolomide and Colorectal Cancer
| Article | Year |
|---|---|
A novel polymerase β inhibitor from phage displayed peptide library augments the anti-tumour effects of temozolomide on colorectal cancer.
Topics: Bacteriophages; Colorectal Neoplasms; DNA Polymerase beta; DNA Repair; Humans; Peptide Library; Temo | 2022 |
Inducing Hypermutability to Promote Anti-PD-1 Therapy Response.
Topics: Colorectal Neoplasms; DNA Mismatch Repair; Humans; Mutation; Temozolomide | 2022 |
BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gene Expression | 2022 |
MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Letter.
Topics: Capecitabine; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methyla | 2020 |
MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response.
Topics: Capecitabine; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methyla | 2020 |
Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Disease Models, A | 2021 |
Temozolomide modulates the expression of miRNAs in colorectal cancer.
Topics: Caco-2 Cells; Colorectal Neoplasms; Down-Regulation; Epigenesis, Genetic; G2 Phase Cell Cycle Checkp | 2021 |
Temozolomide analog PMX 465 downregulates MGMT expression in HCT116 colorectal carcinoma cells.
Topics: Antineoplastic Agents, Alkylating; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enz | 2018 |
The right chance for temozolomide in metastatic colorectal cancer?
Topics: Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Humans; Irinotecan; Methylati | 2018 |
NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells.
Topics: Apoptosis; Benzothiazoles; Cell Cycle; Cell Cycle Checkpoints; Cellular Senescence; Colorectal Neopl | 2015 |
Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Colorectal Neoplasms; Cysteine; Dacarbazine; | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine | 2016 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
MGMT in colorectal cancer: a promising component of personalized treatment.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Colorectal | 2016 |
Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Biopsy; Colectomy; Colorectal Neoplasms; Da | 2011 |
DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Carcin | 2011 |
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; | 2011 |
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiaze | 2004 |
Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.
Topics: Amides; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Colore | 2004 |
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine | 2007 |
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; | 2008 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; | 1998 |